Status:
COMPLETED
Remimazolam Bolus for General Anesthesia
Lead Sponsor:
Gangnam Severance Hospital
Conditions:
Loss of Consciousness
Eligibility:
All Genders
19+ years
Phase:
PHASE3
Brief Summary
It is important to estimate the adequate dose of remimazolam intravenous bolus injection to induce the loss of consciousness. We will determine the ED50 and ED95 of remimazolam intravenous bolus on th...
Eligibility Criteria
Inclusion
- Patients aged 19 years old or older, with American Society of Anesthesiologists Physical Status 1-3, and scheduled for general anesthesia
Exclusion
- Patients scheduled for liver surgery
- Uncontrolled hypertension
- Uncontrolled diabetes mellitus
- Liver disease
- Kidney disease
- Intolerance or hypersensitivity to benzodiazepine
- Addiction
- Glaucoma
- Heart failure
- Peripheral vascular disease
- Obstuctive lung disease
- Patients scheduled for regional anesthesia before general anesthesia
- Pregnancy
Key Trial Info
Start Date :
May 27 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 26 2021
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04901871
Start Date
May 27 2021
End Date
July 26 2021
Last Update
July 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gangnam Severance Hospital
Seoul, South Korea